ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27

ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27

Abstract Anti-HER2 antibodies are effective but often lead to resistance in patients with HER2+ breast cancer. Here, we report an epigenetic crosstalk with aberrant glycerophospholipid metabolism and inflammation as a key resistance mechanism of anti-HER2 therapies in HER2+ breast cancer. Histone re...

Full description

Saved in:
Bibliographic Details
Main Authors: Yong Wang, Yanan Wang, Lei Bao, Goncalo Vale, Jeffrey G. McDonald, Yisheng Fang, Yan Peng, Ashwani Kumar, Chao Xing, Fara Brasó-Maristany, Aleix Prat, Carlos L. Arteaga, Yingfei Wang, Weibo Luo
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-59184-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-59184-5

Similar Items